Ferriprox® (deferiprone) – New formulation approval
May 21, 2020 - Chiesi Global Rare Diseases announced the FDA approval of Ferriprox (deferiprone) twice-a-day 1000 mg oral tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Top